Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass.

Full Abstract

The era of genomics and recombinant DNA technology has ushered in an entirely new class of therapeutic agents designed to influence disease progression at a genetic level. The scope and utility of this technology is not fully realized. However, multiple trials of therapeutic agents have been completed and many more are ongoing. Here we report on edifoligide, a double-stranded oligodeoxynucleotide (ODN) that competitively inhibits the transcription factor E2F, a critical regulator of the cell cycle. Edifoligide has undergone extensive clinical testing for the treatment of intimal hyperplasia following vascular bypass procedures. In this review we address the rationale for targeting E2F in vascular disease, the pharmacology of edifoligide, and the results of preclinical and clinical studies using this novel compound.

Author information

Author/s: Hoel, Andrew W (AW); Conte, Michael S (MS);

Affiliation: Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.

Journal and publication information

Publication Type: Journal Article; Review

Journal: Cardiovascular drug reviews (Cardiovasc Drug Rev), published in United States. (Language: eng)

Reference: 2007-; vol 25 (issue 3) : pp 221-34

Dates: Created 2007/10/08; Completed 2008/01/14;

PMID: 17919257, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.